

**CLODERM® CREAM NOW AVAILABLE
IN ADVANCED PUMP DELIVERY SYSTEM**

FORT WORTH, Texas (October 00, 2007) — Coria Laboratories, Ltd. has announced that Cloderm (clocortolone pivalate) Cream, 0.1% is the first mid-potency corticosteroid to become available in an easy-to-use pump. Known as the Cloderm Pump, the innovative delivery system dispenses a consistent amount of topical therapy for greater precision and safety, while encouraging patient compliance.

In addition to its medical benefits, the Cloderm Pump minimizes waste compared to a similar sized tube, while the larger 30-gram container reduces the need to refill smaller prescription sizes with multiple patient co-pays. The new container fits easily into the palm of the hand and is highly portable and simple to store.

"We believe the Cloderm Pump represents the future of topical corticosteroid delivery because it eliminates the difficulty many patients experience in trying to gauge the proper dosage," said Dr. Duncan Aust, senior vice president of research and development, Coria Laboratories. "Each press of the pump equals approximately one fingertip unit, so the prescribing physician can easily specify the appropriate amount to apply to the affected area."

Cloderm Cream is widely prescribed for the treatment of inflammation and pruritus associated with dermatoses, including atopic dermatitis, seborrheic dermatitis and contact dermatitis. Each 30-gram pump contains approximately 100

(more)

doses, making it an ideal size for treating pediatric patients, facial dermatoses and localized areas of the body.

The advanced therapy has been found to be a highly effective mid-potency steroid with an exceptional safety profile and rapid onset of action as early as day 4 of treatment. In a double-blind, placebo-controlled study of 297 patients with contact dermatitis, atopic dermatitis and seborrheic dermatitis, 60 percent showed good to excellent response to Cloderm by day 7 of treatment, and 87 percent showed good to excellent response within 21 days of therapy.

Cloderm Cream has also been found to have the lowest potential of any mid-potency steroid to cause an allergic reaction on the skin. In other research, it was identified as one of only two topical steroids that have no significant cross-reactivity with other steroids.

The most common adverse events with Cloderm Cream include dryness, irritation, folliculitis, acne-form eruptions, and burning. Cloderm Cream is contraindicated in patients who are hypersensitive to any of the ingredients of this product. As with all topical corticosteroids, systemic absorption can produce reversible HPA-axis suppression.

Coria Laboratories, Ltd., a DFB company, is a rapidly growing pharmaceutical company specializing in research, development and marketing of branded prescription and over-the-counter dermatology products. More information on Coria Laboratories and its products is available by calling 866/819-9007, or by visiting its Web site at www.corialabs.com.

(more)

###

CL-20034